Investegate | Company Announcement

Investegate announcements from Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Related Keywords

Germany ,California ,United States ,San Diego ,American ,Fosun Pharma ,Vinod Balachandran ,Roche Group ,Memorial Sloan Kettering Cancer Center ,American Association For Cancer Research ,Pfizer ,Genentech ,Three Year Phase ,Immune Response ,Delayed Tumor Recurrence ,Some Patients ,Resected Pancreatic ,Chief Medical Officer ,American Association ,Cancer Research ,Annual Meeting ,Good Manufacturing Practice ,New Technologies ,Private Securities Litigation Reform Act ,Annual Report ,